Precipio, Inc. (PRPO)
US — Healthcare Sector
Automate Your Wheel Strategy on PRPO
With Tiblio's Option Bot, you can configure your own wheel strategy including PRPO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRPO
- Rev/Share 13.1452
- Book/Share 8.3964
- PB 2.6881
- Debt/Equity 0.2551
- CurrentRatio 1.2728
- ROIC -0.1202
- MktCap 34690293.0
- FreeCF/Share 0.3597
- PFCF 58.8969
- PE -29.4721
- Debt/Assets 0.1658
- DivYield 0
- ROE -0.1007
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Precipio Stock Up Following Solid Q3 Earnings and Improved Cash Flow
PRPO
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
PRPO reports strong third-quarter 2025 results with higher revenue, positive cash flow and improved margins in core divisions.
Read More
Precipio, Inc. (PRPO) Q3 2025 Earnings Call Prepared Remarks Transcript
PRPO
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Precipio, Inc. ( PRPO ) Q3 2025 Earnings Call November 17, 2025 5:00 PM EST Company Participants Ilan Danieli - Founder, President, CEO & Director Presentation Operator Welcome to the Precipio Third Quarter 2025 Shareholder Update Conference Call. [Operator Instructions] Please note that the conference is being recorded.
Read More
About Precipio, Inc. (PRPO)
- IPO Date 2017-06-30
- Website https://www.precipiodx.com
- Industry Medical - Diagnostics & Research
- CEO Ilan Danieli
- Employees 54
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.